BioSpace News Archive

Be Biopharma, a leader in developing B cells as medicines, founded by Longwood Fund, David Rawlings, MD, and Richard James, PhD, announced a $52 million Series A financing led by Atlas Venture and RA Capital Management and joined by Alta Partners, Longwood Fund and Takeda Ventures, Inc.

zSeres Therapeutics, Inc. announced the expansion of its leadership team with the appointments of David S. Ege, Ph.D., as Executive Vice President, Chief Technology Officer and Jayne M. Gansler as Executive Vice President, Chief People Officer.

KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research involving KP415 and serdexmethylphenidate (SDX) will be featured in two oral presentations during the Annual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Virtual Meeting. In addition, research conducted by KemPharm’s scientific team related to patterns of abuse of

-- ASLAN has initiated recruitment of patients into third dos e cohort at sites in the US, Australia and Singapore following successful safety review of second cohort -- ASLAN004 found to be well tolerated at 400mg dose , third cohort will test 600mg dose

AavantiBio will pursue a diversified gene therapy pipeline, including a lead program in Friedreich’s Ataxia (FA), a rare inherited genetic disease characterized by cardiac and central nervous system dysfunction Bo Cumbo, most recently Sarepta’s Chief Commercial Officer and Executive Vice President, appointed Chief Executive Officer and President of AavantiBio Co-founded by pioneering gene therapy researchers Barry Byrne, M.D., Ph.D., and Manuela Corti, P.T., Ph.D.,

Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, today announced that Amy Everitt , MS, PharmD of Tris’ Medical team wi

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced it will host a conference call and webcast on Sat., Oct. 24 at 11:00 a.m. ET to discuss its presentations at the 2020 EORTC-NCI-AACR Virtual Symposium, including initial clinical data from the dose finding portion of the Phase 1 SHIELD-1 study of drug candidate, TPX-0022, a potent i

Keloid recurrence rate of 10.4% at 12 months for patients treated with SRT following keloidectomy compares with more than 80% with surgical excision alone

KB-0742 is a transcription regulatory network modulator discovered using the company’s proprietary high - throughput screening platform Research s howed KB-0742 i nhibited a ndrogen r eceptor -d ependent a ctivity and r educed t umor g rowth in c astration -r esistant p rostate c ancer Company is on t rack to s ubmit an IND in the fourth quarter of 2020 and i nitiate a Phase 1 /2 clinical trial

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute